Precigen (PGEN) Capital Leases (2012 - 2013)
Precigen (PGEN) reported Capital Leases of $10000.0 for Q4 2013, down 76.19% year-over-year from $42000.0 in Q4 2012, and down 37.5% quarter-over-quarter from $16000.0 in Q3 2013.
Precigen (PGEN) Capital Leases (2012 - 2013) Analysis & Trends
Precigen (PGEN) has 2 years of Capital Leases data on file, last reported at $10000.0 in Q4 2013.
- Capital Leases for Q4 2013 came in at $10000.0, down 76.19% year-over-year; the trailing twelve-month figure through Dec 2013 was $10000.0 (down 76.19% YoY), and the FY2013 annual result was $10000.0, down 76.19% from the prior year.
- Capital Leases slipped to $10000.0 in Q4 2013 per PGEN's latest filing, from $16000.0 in the prior quarter.
- Over five years, Capital Leases peaked at $42000.0 in Q4 2012 and troughed at $10000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 10,000.00 |
| Sep 30, 2013 | 16,000.00 |
| Jun 30, 2013 | 25,000.00 |
| Dec 31, 2012 | 42,000.00 |